IntrinsicIntrinsic

Dividends & Buybacks ·

Quince Therapeutics, Inc. has announced a 1-for-20 reverse stock split, effective at 11:59 pm ET on June 29, 2026…

QNCXIRulya Therapeutics Inc.

Quince Therapeutics, Inc. has announced a 1-for-20 reverse stock split, effective at 11:59 pm ET on June 29, 2026, which will reduce the number of outstanding shares from 19,559,257 to approximately 977,963. Shares will begin trading on a split-adjusted basis on the Nasdaq Global Select Market on June 30, 2026. Quince Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for rare diseases.

More from IRulya Therapeutics Inc.

Explore QNCX